Literature DB >> 11720901

Is the process of beta-cell destruction in type 1 diabetes at time of diagnosis more extensive in females than in males?

P Pozzilli1, C A Mesturino, A Crino, T M Gross, L M Jeng, N Visalli.   

Abstract

OBJECTIVE: To evaluate sex differences in patients with insulin-dependent diabetes mellitus (type 1 diabetes) by comparing the integrated parameters of metabolic control at the time of clinical diagnosis and 3 months after intensive insulin therapy in pre-pubertal, pubertal and post-pubertal patients.
DESIGN: A total of 331 consecutive patients with newly diagnosed type 1 diabetes were studied. The mean age of the group was 15 years (s.d. 8.1; range 5-23 years). Patients were stratified into three groups according to their age at disease onset: pre-pubertal (ages 5-9 years), pubertal (ages 10-18 years) and post-pubertal (ages 19-23 years).
METHODS: Glycated haemoglobin (HbA(1c)), insulin dose and both basal and glucagon-stimulated C-peptide were evaluated at diagnosis and after 3 months of insulin therapy.
RESULTS: We found that females diagnosed after puberty were those with the lowest basal C-peptide compared with males (P=0.005). No statistically significant differences were observed for other metabolic parameters. When the entire group was evaluated, females at the time of diagnosis showed significant lower body mass index (P=0.001), lower basal C-peptide (P=0.021) and higher HbA(1c) (P=0.023) and required more insulin than males (P<0.001). After 3 months of therapy, only a significantly greater dose of insulin was observed in females compared with males (P=0.001), with similar good metabolic control as assessed by HbA(1c).
CONCLUSIONS: We conclude that the process of beta-cell destruction at diagnosis may be more extensive in post-pubertal females than in males. Moreover, after the introduction of insulin therapy, females and males show similar metabolic parameters, although females still require significantly more insulin than males to achieve good metabolic control, 3 months after diagnosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11720901     DOI: 10.1530/eje.0.1450757

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  9 in total

Review 1.  Combination immunotherapies for type 1 diabetes mellitus.

Authors:  Paolo Pozzilli; Ernesto Maddaloni; Raffaella Buzzetti
Journal:  Nat Rev Endocrinol       Date:  2015-02-17       Impact factor: 43.330

2.  Anti-Saccharomyces cerevisiae antibodies are frequent in type 1 diabetes.

Authors:  Wahiba Sakly; Amani Mankaï; Nabil Sakly; Yosra Thabet; Achouak Achour; Leila Ghedira-Besbes; Moncef Jeddi; Ibtissem Ghedira
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

3.  Sex- and season-dependent differences in C-peptide levels at diagnosis of immune-mediated type 1 diabetes.

Authors:  I Weets; I Truyen; I Verschraegen; B Van der Auwera; J De Schepper; H Dorchy; M-C Lebrethon; L Van Gaal; P Van Rooy; D G Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  2006-03-29       Impact factor: 10.122

4.  Clinical evolution of beta cell function in youth with diabetes: the SEARCH for Diabetes in Youth study.

Authors:  D Dabelea; E J Mayer-Davis; J S Andrews; L M Dolan; C Pihoker; R F Hamman; C Greenbaum; S Marcovina; W Fujimoto; B Linder; G Imperatore; R D'Agostino
Journal:  Diabetologia       Date:  2012-09-20       Impact factor: 10.122

5.  A mathematical model for pattern of change in beta-cell reserve and factors affecting residual reserve within the first 2 years of type 1 diabetes.

Authors:  Y Altuntas
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

6.  Spontaneous complete remission of type 1 diabetes mellitus in an adult - review and case report.

Authors:  Harsha Moole; Vishnu Moole; Adrija Mamidipalli; Sowmya Dharmapuri; Raghuveer Boddireddy; Deepak Taneja; Hady Sfeir; Sonia Gajula
Journal:  J Community Hosp Intern Med Perspect       Date:  2015-10-19

7.  Factors Influencing Frequency and Duration of Remission in Children and Adolescents Newly Diagnosed with Type 1 Diabetes.

Authors:  Özlem Kara; İhsan Esen; Derya Tepe
Journal:  Med Sci Monit       Date:  2018-08-28

8.  Features of partial remission in children with type 1 diabetes using the insulin dose-adjusted A1c definition and risk factors associated with nonremission.

Authors:  Tsz Wai Catherine Wong; Man Yee Shirley Wong; Wai Man Betty But
Journal:  Ann Pediatr Endocrinol Metab       Date:  2021-06-30

9.  A predictive model for lack of partial clinical remission in new-onset pediatric type 1 diabetes.

Authors:  Katherine R Marino; Rachel L Lundberg; Aastha Jasrotia; Louise S Maranda; Michael J Thompson; Bruce A Barton; Laura C Alonso; Benjamin Udoka Nwosu
Journal:  PLoS One       Date:  2017-05-01       Impact factor: 3.752

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.